Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamta Garg

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|April 11, 2024
Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guidelineShamez N Ladhani, Savio Fernandes, Mamta Garg, et al.
Bioinformation|June 12, 2026
Prosthetic maintenance profiles and functional performance of single-implant mandibular overdentures in geriatric edentulism: A prospective clinical evaluationDeepinder Kaur, Rishmreet Kaur, Mamta Garg, et al.
British Journal of Haematology|May 8, 2026
Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology GuidelineMamta Garg, Satarupa Choudhuri, Christopher Parrish, et al.
British Journal of Haematology|April 1, 2015
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST TrialAdam J Mead, Dragana Milojkovic, Steven Knapper, et al.
British Journal of Haematology|October 3, 2002
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimensJane E Parker, Tariq Shafi, Antonio Pagliuca, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 22, 2023
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosisSriram Ravichandran, Andrew Hall, Matthew Jenner, et al.
British Journal of Haematology|June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trialAndrew Hall, James Croft, Katrina Walker, et al.
British Journal of Haematology|January 22, 2024
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology GuidelineAustin Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal, et al.
Trials|March 9, 2018
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trialAlina Striha, A John Ashcroft, Anna Hockaday, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|April 11, 2024
Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guidelineShamez N Ladhani, Savio Fernandes, Mamta Garg, et al.
Bioinformation|June 12, 2026
Prosthetic maintenance profiles and functional performance of single-implant mandibular overdentures in geriatric edentulism: A prospective clinical evaluationDeepinder Kaur, Rishmreet Kaur, Mamta Garg, et al.
British Journal of Haematology|May 8, 2026
Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology GuidelineMamta Garg, Satarupa Choudhuri, Christopher Parrish, et al.
British Journal of Haematology|April 1, 2015
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST TrialAdam J Mead, Dragana Milojkovic, Steven Knapper, et al.
British Journal of Haematology|October 3, 2002
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimensJane E Parker, Tariq Shafi, Antonio Pagliuca, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 22, 2023
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosisSriram Ravichandran, Andrew Hall, Matthew Jenner, et al.
British Journal of Haematology|June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trialAndrew Hall, James Croft, Katrina Walker, et al.
British Journal of Haematology|January 22, 2024
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology GuidelineAustin Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal, et al.
Trials|March 9, 2018
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trialAlina Striha, A John Ashcroft, Anna Hockaday, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Pageof 5